Skip to main content
Erschienen in: Breast Cancer Research and Treatment 3/2011

01.12.2011 | Preclinical study

MicroRNA profiles of healthy basal and luminal mammary epithelial cells are distinct and reflected in different breast cancer subtypes

verfasst von: Clemens L. Bockmeyer, Matthias Christgen, Mirco Müller, Sebastian Fischer, Philipp Ahrens, Florian Länger, Hans Kreipe, Ulrich Lehmann

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

In order to determine the microRNA expression pattern in normal basal and luminal breast epithelium and to analyze the relationship of this expression pattern to different breast cancer subtypes, laser-microdissected luminal and basal cells isolated from plastic surgery tissue samples were used for comprehensive expression profiling, measuring 664 microRNAs by low-density TaqMan arrays. In a test (n = 5) and validation set (n = 9) 10 differentially expressed microRNAs were identified by TaqMan RT-qPCR. These microRNAs were studied in laser-microdissected cells of luminal A (n = 5), luminal B (n = 5), basal-like subtypes of breast cancer (n = 10), and malignant myoepithelioma of the breast (n = 10). From 116 microRNAs unequivocally expressed in normal breast epithelial cells, we identified 8 basal microRNAs (let7c, miR-125b, miR-126, miR-127-3p, miR-143, miR-145, miR-146b-5p, and miR-199a-3p), preferentially expressed in normal basal cells, exceeding luminal cells by a factor from 4 to 1000. All of these microRNAs were also found to be significantly elevated in malignant myoepithelioma but not in basal-type of breast cancer. Two members of the miR-200 family (miR-200c and miR-429) were predominantly luminal. Both microRNAs were expressed in the luminal and basal type of breast cancer in contrast to malignant myoepithelioma, which revealed significantly lower levels potentially contributing to its mesenchymal phenotype. In conclusion, normal luminal and basal mammary epithelial cells exhibit a different microRNA expression profile. Malignant myoepithelioma seems to exhibit a basal pattern of microRNA expression, whereas the so-called basal-like breast cancer is clearly different and reveals a luminal type pattern.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Hwang HW, Mendell JT (2006) MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer 94:776–780PubMedCrossRef Hwang HW, Mendell JT (2006) MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer 94:776–780PubMedCrossRef
2.
Zurück zum Zitat Wienholds E, Plasterk RH (2005) MicroRNA function in animal development. FEBS Lett 579:5911–5922PubMedCrossRef Wienholds E, Plasterk RH (2005) MicroRNA function in animal development. FEBS Lett 579:5911–5922PubMedCrossRef
3.
4.
Zurück zum Zitat Younger ST, Pertsemlidis A, Corey DR (2009) Predicting potential MiRNA target sites within gene promoters. Bioorg Med Chem Lett 19(14):3791–3794PubMedCrossRef Younger ST, Pertsemlidis A, Corey DR (2009) Predicting potential MiRNA target sites within gene promoters. Bioorg Med Chem Lett 19(14):3791–3794PubMedCrossRef
5.
Zurück zum Zitat Gregory PA, Bert AG, Paterson EL et al (2008) The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 10:593–601PubMedCrossRef Gregory PA, Bert AG, Paterson EL et al (2008) The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 10:593–601PubMedCrossRef
6.
Zurück zum Zitat Mattie MD, Benz CC, Bowers J et al (2006) Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer 5:24PubMedCrossRef Mattie MD, Benz CC, Bowers J et al (2006) Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer 5:24PubMedCrossRef
7.
Zurück zum Zitat Blenkiron C, Goldstein LD, Thorne NP et al (2007) MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol 8:R214PubMedCrossRef Blenkiron C, Goldstein LD, Thorne NP et al (2007) MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol 8:R214PubMedCrossRef
8.
Zurück zum Zitat Verghese ET, Hanby AM, Speirs V et al (2008) Small is beautiful: microRNAs and breast cancer-where are we now? J Pathol 215:214–221PubMedCrossRef Verghese ET, Hanby AM, Speirs V et al (2008) Small is beautiful: microRNAs and breast cancer-where are we now? J Pathol 215:214–221PubMedCrossRef
9.
Zurück zum Zitat Volinia S, Calin GA, Liu CG et al (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci 103:2257–2261PubMedCrossRef Volinia S, Calin GA, Liu CG et al (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci 103:2257–2261PubMedCrossRef
10.
Zurück zum Zitat Sempere LF, Christensen M, Silahtaroglu A et al (2007) Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res 67:11612–11620PubMedCrossRef Sempere LF, Christensen M, Silahtaroglu A et al (2007) Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res 67:11612–11620PubMedCrossRef
11.
Zurück zum Zitat Buza N, Zekry N, Charpin C, Tavassoli FA (2010) Myoepithelial carcinoma of the breast: a clinicopathological and immunohistochemical study of 15 diagnostically challenging cases. Virchows Arch. doi: 10.1007/s00428-010-0950-4 Buza N, Zekry N, Charpin C, Tavassoli FA (2010) Myoepithelial carcinoma of the breast: a clinicopathological and immunohistochemical study of 15 diagnostically challenging cases. Virchows Arch. doi: 10.​1007/​s00428-010-0950-4
12.
Zurück zum Zitat Cheang MC, Chia SK, Voduc D et al (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101:736–750PubMedCrossRef Cheang MC, Chia SK, Voduc D et al (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101:736–750PubMedCrossRef
13.
Zurück zum Zitat Thike AA, Cheok PY, Jara-Lazaro AR et al (2010) Triple negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer. Mod Pathol 23:123–133PubMedCrossRef Thike AA, Cheok PY, Jara-Lazaro AR et al (2010) Triple negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer. Mod Pathol 23:123–133PubMedCrossRef
14.
Zurück zum Zitat Livasy CA, Karaca G, Nanda R et al (2006) Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 19:264–271PubMedCrossRef Livasy CA, Karaca G, Nanda R et al (2006) Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 19:264–271PubMedCrossRef
15.
Zurück zum Zitat Theophile K, Hussein K, Kreipe H et al (2008) Expression profiling of apoptosis-related genes in megakaryocytes: BNIP3 is downregulated in primary myelofibrosis. Exp Hematol 36:1728–1738PubMedCrossRef Theophile K, Hussein K, Kreipe H et al (2008) Expression profiling of apoptosis-related genes in megakaryocytes: BNIP3 is downregulated in primary myelofibrosis. Exp Hematol 36:1728–1738PubMedCrossRef
16.
Zurück zum Zitat Tang F, Hajkova P, Barton SC et al (2006) MicroRNA expression profiling of single whole embryonic stem cells. Nucl Acids Res 34:e9PubMedCrossRef Tang F, Hajkova P, Barton SC et al (2006) MicroRNA expression profiling of single whole embryonic stem cells. Nucl Acids Res 34:e9PubMedCrossRef
17.
Zurück zum Zitat Mestdagh P, Feys T, Bernard N et al (2008) High-throughput stem-loop RT-qPCR miRNA expression profiling using minute amounts of input RNA. Nucl Acids Res 36:e143PubMedCrossRef Mestdagh P, Feys T, Bernard N et al (2008) High-throughput stem-loop RT-qPCR miRNA expression profiling using minute amounts of input RNA. Nucl Acids Res 36:e143PubMedCrossRef
18.
Zurück zum Zitat Andersen CL, Jensen JL, Ørntoft TF (2004) Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res 64:5245–5250PubMedCrossRef Andersen CL, Jensen JL, Ørntoft TF (2004) Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res 64:5245–5250PubMedCrossRef
19.
Zurück zum Zitat Vandesompele J, De Preter K, Pattyn F et al (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3:34.1–34.11CrossRef Vandesompele J, De Preter K, Pattyn F et al (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3:34.1–34.11CrossRef
20.
Zurück zum Zitat Boecker W, Moll R, Dervan P et al (2002) Usual ductal hyperplasia of the breast is a committed stem (progenitor) cell lesion distinct from atypical ductal hyperplasia and ductal carcinoma in situ. J Pathol 198:458–467PubMedCrossRef Boecker W, Moll R, Dervan P et al (2002) Usual ductal hyperplasia of the breast is a committed stem (progenitor) cell lesion distinct from atypical ductal hyperplasia and ductal carcinoma in situ. J Pathol 198:458–467PubMedCrossRef
21.
Zurück zum Zitat Jones C, Mackay A, Grigoriadis A et al (2004) Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of novel prognostic markers for breast cancer. Cancer Res 64:3037–3045PubMedCrossRef Jones C, Mackay A, Grigoriadis A et al (2004) Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of novel prognostic markers for breast cancer. Cancer Res 64:3037–3045PubMedCrossRef
22.
Zurück zum Zitat Khoshnaw SM, Green AR, Powe DG et al (2009) MicroRNA involvement in the pathogenesis and management of breast cancer. Clin Pathol 62:422–428 (Review)CrossRef Khoshnaw SM, Green AR, Powe DG et al (2009) MicroRNA involvement in the pathogenesis and management of breast cancer. Clin Pathol 62:422–428 (Review)CrossRef
23.
Zurück zum Zitat Ng EK, Wong CL, Ma ES et al (2009) MicroRNAs as new players for diagnosis, prognosis, and therapeutic targets in breast cancer. J Oncol 2009:305420 Ng EK, Wong CL, Ma ES et al (2009) MicroRNAs as new players for diagnosis, prognosis, and therapeutic targets in breast cancer. J Oncol 2009:305420
24.
Zurück zum Zitat Charafe-Jauffret E, Ginestier C, Monville F et al (2006) Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene 25:2273–2284PubMedCrossRef Charafe-Jauffret E, Ginestier C, Monville F et al (2006) Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene 25:2273–2284PubMedCrossRef
25.
Zurück zum Zitat Davoren PA, McNeill RE, Lowery AJ et al (2008) Identification of suitable endogenous control genes for microRNA gene expression analysis in human breast cancer. BMC Mol Biol 9:76PubMedCrossRef Davoren PA, McNeill RE, Lowery AJ et al (2008) Identification of suitable endogenous control genes for microRNA gene expression analysis in human breast cancer. BMC Mol Biol 9:76PubMedCrossRef
26.
Zurück zum Zitat Hui AB, Shi W, Boutros PC et al (2009) Robust global micro-RNA profiling with formalin-fixed paraffin-embedded breast cancer tissues. Lab Invest 89:597–606PubMedCrossRef Hui AB, Shi W, Boutros PC et al (2009) Robust global micro-RNA profiling with formalin-fixed paraffin-embedded breast cancer tissues. Lab Invest 89:597–606PubMedCrossRef
27.
Zurück zum Zitat Avril-Sassen S, Goldstein LD, Stingl J, et al. Characterisation of microRNA expression in post-natal mouse mammary gland development. BMC Genomics 10:548 Avril-Sassen S, Goldstein LD, Stingl J, et al. Characterisation of microRNA expression in post-natal mouse mammary gland development. BMC Genomics 10:548
28.
Zurück zum Zitat Lee EJ, Baek M, Gusev Y et al (2008) Systematic evaluation of microRNA processing patterns in tissues, cell lines, and tumors. RNA 14:35–42PubMedCrossRef Lee EJ, Baek M, Gusev Y et al (2008) Systematic evaluation of microRNA processing patterns in tissues, cell lines, and tumors. RNA 14:35–42PubMedCrossRef
29.
Zurück zum Zitat Lu J, Getz G, Miska EA et al (2005) MicroRNA expression profiles classify human cancers. Nature 435:834–838PubMedCrossRef Lu J, Getz G, Miska EA et al (2005) MicroRNA expression profiles classify human cancers. Nature 435:834–838PubMedCrossRef
30.
Zurück zum Zitat Sachdeva M, Mo YY (2010) MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1. Cancer Res 70:378–387PubMedCrossRef Sachdeva M, Mo YY (2010) MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1. Cancer Res 70:378–387PubMedCrossRef
31.
Zurück zum Zitat Kohlgraf KG, Gawron AJ, Higashi M et al (2003) Contribution of the MUC1 tandem repeat and cytoplasmic tail to invasive and metastatic properties of a pancreatic cancer cell line. Cancer Res 63:5011–5020PubMed Kohlgraf KG, Gawron AJ, Higashi M et al (2003) Contribution of the MUC1 tandem repeat and cytoplasmic tail to invasive and metastatic properties of a pancreatic cancer cell line. Cancer Res 63:5011–5020PubMed
32.
Zurück zum Zitat Dykxhoorn DM, Wu Y, Xie H (2009) miR-200 enhances mouse breast cancer cell colonization to form distant metastases. PLoS One 4:e7181 Dykxhoorn DM, Wu Y, Xie H (2009) miR-200 enhances mouse breast cancer cell colonization to form distant metastases. PLoS One 4:e7181
33.
Zurück zum Zitat Neves R, Scheel C, Weinhold S et al (2010) Role of DNA methylation in miR-200c/141 cluster silencing in invasive breast cancer cells. BMC Res Notes 3:219PubMedCrossRef Neves R, Scheel C, Weinhold S et al (2010) Role of DNA methylation in miR-200c/141 cluster silencing in invasive breast cancer cells. BMC Res Notes 3:219PubMedCrossRef
34.
Zurück zum Zitat Hu X, Macdonald DM, Huettner PC et al (2009) A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer. Gynecol Oncol 114:457–464PubMedCrossRef Hu X, Macdonald DM, Huettner PC et al (2009) A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer. Gynecol Oncol 114:457–464PubMedCrossRef
35.
Zurück zum Zitat Liu H, Kohane IS (2009) Tissue and process specific microRNA-mRNA co-expression in mammalian development and malignancy. PLoS One 4:e5436PubMedCrossRef Liu H, Kohane IS (2009) Tissue and process specific microRNA-mRNA co-expression in mammalian development and malignancy. PLoS One 4:e5436PubMedCrossRef
36.
Zurück zum Zitat Petersen OW, Lind Nielsen H, Gudjonsson T et al (2001) The plasticity of human breast carcinoma cells is more than epithelial to mesenchymal conversion. Breast Cancer Res 3:213–217PubMedCrossRef Petersen OW, Lind Nielsen H, Gudjonsson T et al (2001) The plasticity of human breast carcinoma cells is more than epithelial to mesenchymal conversion. Breast Cancer Res 3:213–217PubMedCrossRef
Metadaten
Titel
MicroRNA profiles of healthy basal and luminal mammary epithelial cells are distinct and reflected in different breast cancer subtypes
verfasst von
Clemens L. Bockmeyer
Matthias Christgen
Mirco Müller
Sebastian Fischer
Philipp Ahrens
Florian Länger
Hans Kreipe
Ulrich Lehmann
Publikationsdatum
01.12.2011
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2011
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-010-1303-3

Weitere Artikel der Ausgabe 3/2011

Breast Cancer Research and Treatment 3/2011 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.